Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427573 | 0.88 | LMNA (0.73) | CASP6KMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL6427127 | 0.84 | MAPT (0.72) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL6428395 | 0.84 | CASP6 (0.68) | CASP6MAPTRAB9AALDH1A1LMNA | |
| SCHEMBL6427130 | 0.81 | MEN1 (1.00) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL6360182 | 0.80 | LMNA (0.68) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL6428110 | 0.79 | MEN1 (0.59) | CASP6KMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL13753324 | 0.77 | LMNA (0.71) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL8846633 | 0.76 | LMNA (0.59) | CASP6KMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL15618832 | 0.75 | RAB9A (0.77) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL6427707 | 0.75 | LMNA (0.64) | KMT2AMEN1MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | claimed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | CASP6 3626/4885KMT2A 2476/4885MEN1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.